Right, some people were aware of these issues and hoped that SMI overcomes them
(edit: I do question how many of the participants actually were aware of this, given the attempts in this thread to chill discussion)
Not saying that's dumb, I just don't see how that's likely in the absence of dosage and pk information unless explicitly accounted for in a group experiment...
These quotes demonstrate that you're effectively taking the uncertainties of one preclinical drug (HMI) and multiplying them by those of another preclinical drug (SMI):
-"future structural modifications of SMI-6 should be undertaken so as to increase its therapeutic window"
-"This report represents an early pre-clinical phase"
-"should be further optimized and improved before it can be considered as therapeutics"
-"a more complete characterization of the pharmacodynamics and metabolic stability of SMI-6"
-"a determination of its oral deliverability"
-"resolution of the exact mechanism which governs the PRLR independent anti-tumorigenic action of SMI-6"